-+ 0.00%
-+ 0.00%
-+ 0.00%
Huadong Pharmaceutical (000963.SZ) subsidiary HDM4002 injection clinical trial application approved
Share
Listen to the news

Zhitong Finance App News, Huadong Pharmaceutical (000963.SZ) issued an announcement. On November 17, 2026, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“China-US Huadong”), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the National Drug Administration (NMPA), and the HDM4002 injection clinical trial application submitted by China and US Huadong was approved. This drug is used to treat adult patients with primary immunoglobulin A (IgA) nephropathy who are at risk of disease progression to reduce loss of renal function. This approval is an important step forward in the product development process and will further enhance the company's core competitiveness in the field of autoimmune treatment.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending